Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases

✍ Scribed by Thomas J. Polascik; Robert W. Given; Charles Metzger; Sydney R. Julian; James C. Vestal; Gary S. Karlin; Craig S. Barkley; David L. Bilhartz; Laura T. McWhorter; Leo V. Lacerna

• Book ID: 116945195
• Publisher: Elsevier Science
• Year: 2005
• Tongue: English
• Weight: 133 KB
• Volume: 66
• Category: Article
• ISSN: 0090-4295
• DOI: 10.1016/j.urology.2005.05.035